[EN] PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS<br/>[FR] PYRROLOTRIAZINES EN TANT QU'INHIBITEURS D'ALK ET DE JAK2
申请人:CEPHALON INC
公开号:WO2010071885A1
公开(公告)日:2010-06-24
The present invention provides a compound of formula (I) or a salt form thereof, wherein Q1, Q2, Q3, and Q4 are as defined herein. The compound of formula (I) has ALK and/or JAK2 inhibitory activity, and may be used to treat proliferative disorders.
N,N-Dialkyl-N′-arylhydrazines have been prepared usually in high to excellent yields via the reaction of N,N-dialkylhydrazines with arylchlorides in the presence of Pd2(dba)3, Xphos and NaO-t-Bu in dioxane at 120 °C. With ortho-substituted arylchlorides best results have been obtained by using 2-(2′,6′-dimethoxybiphenyl)dicyclohexylphosphine (ligand d) as the ligand.
New Phosphine-Functionalized NHC Ligands: Discovery of an Effective Catalyst for the Room-Temperature Amination of Aryl Chlorides with Primary and Secondary Amines
作者:Craig A. Wheaton、John-Paul J. Bow、Mark Stradiotto
DOI:10.1021/om400684n
日期:2013.11.11
dihydroimidazolium salts and demonstrate their utility as ligand precursors for Buchwald–Hartwig amination. Several examples of the general formula [1-Mes-3-2-(PR2)phenyl}imidazolidin-2-ylium][BF4] have been prepared, where phosphines of varying steric and electronic properties (R = Ph (9), Cy (10), 1-Ad (11)) are tethered by an o-phenylene group. The synthesis was not adaptable to N-aryl groups other than mesityl
Addressing Challenges in Palladium-Catalyzed Cross-Couplings of Aryl Mesylates: Monoarylation of Ketones and Primary Alkyl Amines
作者:Pamela G. Alsabeh、Mark Stradiotto
DOI:10.1002/anie.201303305
日期:2013.7.8
Mor(DalPhos) for Me(sylates): Described are the first examples of ketone mono‐α‐arylation and primary aliphatic aminemonoarylation employing aryl methanesulfonate coupling partners. A range of functionalized arylmesylates were employed with dialkyl ketones, and also with primary and secondary amines as well as the otherwise challenging coupling partners acetone and methylamine. Ad=adamantyl.
The present invention relates to compounds that are useful as inhibitors of the activity of Wee-1 kinase. The present invention also relates to pharmaceutical compositions comprising these compounds and to methods of using these compounds in the treatment of cancer and methods of treating cancer.